David Oppenheim - Concepedia

Concepedia

Author

David Oppenheim

Also Known As

D E Oppenheim, D Oppenheim, D. E. Oppenheim, D. Oppenheim, David E Oppenheim, David E. Oppenheim, David Oppenheim

23

Publications

1.6K

Citations

9

H-Index

19

Concepts

All Affiliations

Guy's Hospital Roche (Switzerland)King's College London Institut Gustave Roussy Institut Claudius Regaud

DO

About

David Oppenheim is an author at Guy's Hospital specializing in medicine, immunotherapy, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	516
2	Immunology	3	3	490
3	Cell Biology	2	2	470
4	Cancer Therapeutics	2	2	46
5	Pathology	1	1	26

David Oppenheim

×

8

Publications

1.6K

Citations

8

H-Index

	Year	Citations
Regulation of Cutaneous Malignancy by γδ T Cells Michael Girardi, David Oppenheim, Carrie R. Steele, Science	2001	964
Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance David Oppenheim, Scott Roberts, Sarah L. Clarke, Nature Immunology Nkg2d ReceptorNatural CytotoxicityNatural Killer CellsCancer ImmunosurveillanceImmunology	2005	433
Pillars Article: Regulation of Cutaneous Malignancy by γδ T Cells. <i>Science</i>. 2001. 294: 605-609. Michael Girardi, David Oppenheim, Carrie R. Steele, PubMed	2018	63
Intraluminal fibrosis induced unilaterally by lobar instillation of CdCl2 into the rat lung. V.V. Damiano, Plammoottil V. Cherian, F R Frankel, PubMed	1990	37
Characterizing the Protective Component of the αβ T Cell Response to Transplantable Squamous Cell Carcinoma Michael Girardi, David Oppenheim, Earl J. Glusac, Journal of Investigative Dermatology Cancer ImmunosurveillanceT-regulatory CellImmunologyProtective ComponentCell Biology	2004	37
Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy David Oppenheim, Roberto Spreafico, Annie Etuk, British Journal of Cancer	2014	28
Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma Jean‐Pierre Delord, Josep Tabernero, Rocio García‐Carbonero, European Journal of Cancer MedicineMulticentre Expansion CohortColorectal CancerPathologyImmune Checkpoint Inhibitor	2013	26
An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma Stéphane Temam, James Spicer, Farzin Farzaneh, Annals of Oncology MedicineOperable HeadImmunologyImmune Checkpoint InhibitorHead And Neck Cancer	2017	20

Page 1